Swiss Biotech Association secured 15% discount for Members of the association.
With the rapid spread of the coronavirus pandemic this is a timely review of the industry response to the crisis. Among the topics covered during the 6th Annual Immuno-Oncology Innovation Forum are revised development strategies and clinical trials, as well as the challenge of finance and investment for biotechs. With the cancellation of the major industry conferences, this digital event allows the IO community to be updated on the most recent developments and to network with colleagues from across the world using our online video meeting platform. We are keen to support our community and, with the virtual conference, can offer all the benefits attendees would usually expect.
The #Sachs_IOIF brings together leaders from cancer research institutes, patient advocacy groups, early and late-stage investors, pharmas and biotechs. The programme will cover licensing and investment opportunities in the immuno-oncology field.